Drug
MK-4827
MK-4827 is a pharmaceutical drug with 5 clinical trials. Historical success rate of 50.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 2 completed trials
Completion Rate
50%(2/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
2(40%)
Phase Distribution
Ph phase_1
4
80%
Ph phase_2
1
20%
Phase Distribution
4
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
4(80.0%)
Phase 2Efficacy & side effects
1(20.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
40.0%
2 of 5 finished
Non-Completion Rate
60.0%
3 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(2)
Terminated(3)
Detailed Status
Completed2
Terminated2
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
50.0%
Most Advanced
Phase 2
Trials by Phase
Phase 14 (80.0%)
Phase 21 (20.0%)
Trials by Status
withdrawn120%
completed240%
terminated240%
Recent Activity
0 active trials
Showing 5 of 5
withdrawnphase_2
A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002)
NCT01244009
terminatedphase_1
A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1)
NCT01110603
completedphase_1
A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)
NCT00749502
completedphase_1
Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)
NCT01294735
terminatedphase_1
A Phase I Study of MK-4827 for Treatment of Solid Tumors (MK-4827-005)
NCT01226901
Clinical Trials (5)
Showing 5 of 5 trials
NCT01244009Phase 2
A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002)
NCT01110603Phase 1
A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1)
NCT00749502Phase 1
A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)
NCT01294735Phase 1
Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)
NCT01226901Phase 1
A Phase I Study of MK-4827 for Treatment of Solid Tumors (MK-4827-005)
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5